Literature DB >> 31750100

An Immunohistochemical Study of HIF-1 Alpha in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma.

Nikita Rajendrakumar Patel1, Leena Jain2, Aarti Mahendra Mahajan3, Poonam Vilas Hiray4, Sandeep S Shinde5, Pranjal A Patel6.   

Abstract

To evaluate and compare the expression of HIF-1 Alpha (HIF-1α) in oral epithelial dysplasia (OED) and various grades of Oral squamous cell carcinoma (OSCC). 30 cases each of OEDand OSCC were stained with HIF-1α antibody. Quantification of HIF-1α positive cellswas carried out and the data was statistically analysed. The mean % HIF-1α labeling index (HIF-1α LI) increased significantly from mild OED (32.11%), moderate OED (55.07%), to severe OED (64.58%). There was a statistically significant increase in the expression of HIF-1α as grades of OED increased. The mean HIF-1α LI % in well differentiated OSCC was 46.3%, Moderately differentiated OSCC-76.31% and Poorly differentiated OSCC-89.9%. The mean HIF-1α LI was found to increase with increasing grades of OSCC which was statistically significant (P < 0.05). Further a comparison of mean HIF-1α LI in OED with different histologic grades of OSCC by Independent samples t test was performed. We found statistically significant difference between OED and moderately differentiated OSCC and OED and poorly differentiated OSCC (P = 0.000). Progressive increase in expression of HIF-1α was noted from OED to OSCC. It can be postulated that epithelial dysplastic lesions with increased HIF-1α expression are at greater risk of malignant transformation, suggesting that the expression of HIF-1α is an early event in oral carcinogenesis. © Association of Otolaryngologists of India 2019.

Entities:  

Keywords:  HIF-1α; Immunohistochemistry; OSCC; Oral epithelial dysplasia

Year:  2019        PMID: 31750100      PMCID: PMC6838271          DOI: 10.1007/s12070-019-01597-y

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  18 in total

1.  Oral premalignancy: new methods of detection and treatment.

Authors:  Ann Gillenwater; Vali Papadimitrakopoulou; Rebecca Richards-Kortum
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

Review 2.  Potentially malignant disorders of the oral cavity: current practice and future directions in the clinic and laboratory.

Authors:  Kalen R Dionne; Saman Warnakulasuriya; Rosnah Binti Zain; Sok Ching Cheong
Journal:  Int J Cancer       Date:  2014-02-11       Impact factor: 7.396

Review 3.  Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

Authors:  Nadine Rohwer; Thorsten Cramer
Journal:  Drug Resist Updat       Date:  2011-04-03       Impact factor: 18.500

4.  New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas.

Authors:  M Bryne; H S Koppang; R Lilleng; T Stene; G Bang; E Dabelsteen
Journal:  J Oral Pathol Med       Date:  1989-09       Impact factor: 4.253

5.  Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan.

Authors:  Pin-Yi Lin; Chuan-Hang Yu; Jeng-Tzung Wang; Huang-Hsu Chen; Shih-Jung Cheng; Mark Yen-Ping Kuo; Chun-Pin Chiang
Journal:  J Oral Pathol Med       Date:  2008-01       Impact factor: 4.253

6.  Hypoxia-inducible factor 1 alpha in oral squamous cell carcinoma and its relation to prognosis.

Authors:  Masataka Uehara; Kazuo Sano; Hisazumi Ikeda; Mihoko Nonaka; Izumi Asahina
Journal:  Oral Oncol       Date:  2009-03       Impact factor: 5.337

7.  HIF1-alpha expression predicts survival of patients with squamous cell carcinoma of the oral cavity.

Authors:  Marcelo dos Santos; Ana Maria da Cunha Mercante; Iúri Drumond Louro; Antônio José Gonçalves; Marcos Brasilino de Carvalho; Eloiza Helena Tajara da Silva; Adriana Madeira Álvares da Silva
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

8.  Hypoxia in head and neck squamous cell carcinoma.

Authors:  John Zenghong Li; Wei Gao; Jimmy Yu-Wai Chan; Wai-Kuen Ho; Thian-Sze Wong
Journal:  ISRN Otolaryngol       Date:  2012-10-16

9.  HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor.

Authors:  Thomas Fillies; Richard Werkmeister; Paul J van Diest; Burkhard Brandt; Ulrich Joos; Horst Buerger
Journal:  BMC Cancer       Date:  2005-07-21       Impact factor: 4.430

10.  Clinical and prognostic significance of HIF-1α overexpression in oral squamous cell carcinoma: a meta-analysis.

Authors:  Jianhua Zhou; Shengyun Huang; Lili Wang; Xiao Yuan; Quanjiang Dong; Dongsheng Zhang; Xuxia Wang
Journal:  World J Surg Oncol       Date:  2017-05-18       Impact factor: 2.754

View more
  4 in total

Review 1.  Different polymorphisms in HIF-1α may exhibit different effects on cancer risk in Asians: evidence from nearly forty thousand participants.

Authors:  Yichen Liu; Xiaoqi Zhu; Xiaoyi Zhou; Jingwen Cheng; Xiaoyu Fu; Jingsheng Xu; Yuya Wang; Yueping Zhong; Minjie Chu
Journal:  Aging (Albany NY)       Date:  2020-11-04       Impact factor: 5.682

2.  Comparison of Androgen Receptor, VEGF, HIF-1, Ki67 and MMP9 Expression between Non-Metastatic and Metastatic Stages in Stromal and Tumor Cells of Oral Squamous Cell Carcinoma.

Authors:  Lovorka Batelja-Vuletic; Cedna Tomasovic-Loncaric; Marcello Ceppi; Marco Bruzzone; Aleksandra Fucic; Karolina Krstanac; Vanja Boras Vucicevic
Journal:  Life (Basel)       Date:  2021-04-10

3.  PD-L1 in Combination with CD8+TIL and HIF-1α are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma.

Authors:  Zihan Zhou; Dianbin Mu; Dexian Zhang; Xianbin Zhang; Xingchen Ding; Jia Yang; Xinbin Bai; Man Hu
Journal:  Cancer Manag Res       Date:  2020-12-23       Impact factor: 3.989

Review 4.  Current Understanding of the HIF-1-Dependent Metabolism in Oral Squamous Cell Carcinoma.

Authors:  Alexander W Eckert; Matthias Kappler; Ivo Große; Claudia Wickenhauser; Barbara Seliger
Journal:  Int J Mol Sci       Date:  2020-08-24       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.